Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Extranodal NK-T-Cell 1Lymphoma, B-Cell, Marginal Zone 1Enteropathy-Associated T-Cell Lymphoma 1

Interventions

Rituximab 19Cyclophosphamide 12Peripheral Blood Stem Cell Transplantation 10Filgrastim 10fludarabine phosphate 9Bortezomib 9Radiotherapy 8Cyclosporine 8tanespimycin 6Prednisone 6Magnetic Resonance Spectroscopy 6Etoposide 6Vorinostat 5Vincristine 5Lenalidomide 5Indium 5Ifosfamide 5temsirolimus 4bryostatin 1 4alvocidib 4Paclitaxel 4Interferon-alpha 4Gemcitabine 4Doxorubicin 4Cytarabine 4Busulfan 4sargramostim 3ibrutinib 3apolizumab 3aldesleukin 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Lymphoma, B-Cell, Marginal Zone × cc-486 × Clear all
NCT04799275 2026-05-13

Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma

National Cancer Institute (NCI)

Phase 2/3 Active not recruiting
422 enrolled
Lymphoid

Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone

Data powered by HemOnc (CC BY 4.0) Colophon âš¡